Overview
- A federal jury in Boston, which reached its verdict Monday, said Takeda used an anticompetitive scheme to stall cheaper versions of Amitiza and set single damages at about $884.9 million.
- At issue was a 2014 deal that let Par Pharmaceutical delay a generic until January 2021 in return for selling an authorized version under a profit‑sharing plan that plaintiffs valued at about $210 million.
- The award includes about $474.9 million for wholesalers and pharmacies, $63.2 million for insurers and other end payors, and retailer wins such as $191 million for CVS and $121 million for Walgreens, with some end‑payor recovery still awaiting court steps.
- The ruling is the first time a federal jury has found a drugmaker liable in a pay‑for‑delay case, a type of settlement where a brand‑name company pays a generic rival to hold back a lower‑cost copy.
- Takeda said it will file post‑trial motions and appeal and is reviewing how to book any provision, adding that its FY2026 outlook should largely stand except for adjusted free cash flow.